9results about How to "Reduce vitality" patented technology

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

The invention provides application of TMEM65 in construction of a myocardial injury animal model and preparation of a medicine for treating myocardial injury. A TMEM65 myocardial cell specific knockout mouse is constructed through a CRISPR / Cas9 technology, and the physiological action of the TMEM65 gene in myocardial cells can be more accurately researched. By observing the phenotypic change of the TMEM65 myocardial cell specific knockout mouse, the effect and mechanism of TMEM65 in the generation and development of sepsis can be explored. Furthermore, experiments show that TMEM65 overexpression significantly improves the decrease of LPS-induced myocardial cell viability, reduces LDH release, and reduces the apoptosis rate, thereby proving the hypothesis that TMEM65 plays a protective role in sepsis myocardial injury.

The invention relates to the technical field of animal model construction, in particular to a construction method and application of a gene editing mouse model for studying calcium library function and low fertility in mature sperms.The model is characterized in that tamoxifen is used for inducing, a Ddx4ERT2 promoter is used for driving Cre recombinase expression, three subtypes of IP3R are specifically knocked out in sperms at the same time, and the mouse model is obtained. The method is used for researching the action and mechanism of the subtype in male fertility. After the model mouse is subjected to two rounds of induced knockout, the fertility is severely damaged, the sperm quantity and movement level are reduced, and the acrosome reaction is abnormal, so that the model is a good model for evaluating the sperm dysfunction, and is expected to be used for screening treatment drugs for improving the sperm dysfunction, especially male sterility diseases caused by advanced acrosome reaction in the future. In addition, through screening optimization of an IP3R agonist and a calcium signal detection platform, it is further confirmed that the mouse model is a good model for studying sperm calcium library mediated calcium signals.

This invention belongs to the field of plant genetic engineering, specifically relating to an isolated nucleic acid molecule encoding the Sapindus mukorossi SmHD-ZIP34 protein and its application. The isolated nucleic acid molecule has a nucleotide sequence as shown in SEQ ID NO.1, or encodes an amino acid sequence as shown in SEQ ID NO.2. This invention reveals for the first time the dual function of this isolated nucleic acid molecule in simultaneously regulating flowering time and sex differentiation in plants. Experiments have shown that overexpression of this nucleic acid molecule in Arabidopsis thaliana significantly promotes flowering and pistil elongation, and inhibits stamen development by downregulating the core pathway of stamen development, leading to a reduction in the number of stamens and pollen abortion. The nucleic acid molecule resource provided by this invention offers an effective solution to the problems of long breeding cycles and low fruit set rates due to male flower dominance in economic forest trees such as Sapindus mukorossi, and can be used to cultivate high-yielding new germplasm with early flowering, fewer males, and more females.

The application provides an application of a CNOT9 expression inhibitor in preparation of a medicine for preventing, alleviating and / or treating liver cancer. It is found for the first time that the mRNA and protein expression levels of CNOT9 in hepatocellular carcinoma (HCC) tissues are significantly higher than those in paracancerous and normal liver tissues, and the high expression is closely related to the prognosis indexes such as the overall survival and progression-free survival of patients, thereby establishing the value of CNOT9 as a liver cancer diagnosis marker and a new treatment target. Based on this, the application provides an application of a CNOT9 inhibitor in preparation of a medicine for preventing, alleviating and / or treating liver cancer. By down-regulating the expression of CNOT9 through siRNA, the proliferation activity, clonogenicity, migration and invasion ability of liver cancer cells HLF can be effectively inhibited. The application further provides a medicine composition comprising the inhibitor, thereby providing a brand-new target and effective intervention strategy for liver cancer treatment, and having a great clinical development prospect and application value.

This invention provides a strain of *Lactobacillus paragrigii* and its application in products for the prevention and treatment of liver cancer, belonging to the field of biomedicine. This invention provides a strain of *Lactobacillus paragrigii* (… Lactobacillus paragassers Lactobacillus parageri JMS024, with accession number CGMCC No. 33909, was deposited at the China General Microbiological Culture Collection Center on March 20, 2025. This invention describes the isolation of extracellular vesicles from Lactobacillus parageri JMS024 through culturing. These vesicles significantly inhibit the proliferation, migration, and autophagy of liver cancer cells, and significantly reduce their activity. They can be used to prepare products for the treatment of liver cancer.

The invention provides an application of fusion protein overexpression in reduction of uranium-induced mitochondrial dysfunction, the fusion protein comprises Mfn1 or Opa1, kidney injury caused by uranium is repaired through overexpression of the fusion protein Mfn1 or Opa1, the overexpression of the fusion protein Mfn1 or Opa1 is used for reducing uranium-induced malondialdehyde concentration increase, and the uranium-induced mitochondrial dysfunction can be reduced through the overexpression of the fusion protein Mfn1 or Opa1. The reduction of glutathione and SOD enzyme activity caused by uranium is improved, and the reduction of ATP caused by uranium is recovered.

This invention discloses the application of ZFP36 as a target in anti-non-small cell lung cancer (NSCLC) drugs and pharmaceutical compositions, belonging to the field of biomedical technology. The invention upregulates ZFP36 expression or enhances its RNA-binding activity, utilizing the zinc finger domain composed of amino acids 115-148 of the ZFP36 protein to specifically bind to the ATTTA-type ARE motif of the FASN mRNA 3'UTR and promote target mRNA degradation, thereby downregulating the expression of FASN, lipid droplet-related proteins, and CD36, thus triple-inhibiting lipid droplet metabolism. Simultaneously, it inhibits CAF secretion of lipid carriers, blocking lipid transport and metabolic remodeling in the tumor microenvironment. This invention can inhibit NSCLC cell proliferation, induce apoptosis, and reverse chemotherapy resistance. It clarifies that ZFP36-related biomarkers can be used for lung cancer chemotherapy resistance subtyping and targeted efficacy prediction, providing a novel target and approach for precision treatment of NSCLC, and possessing excellent clinical translational value.